Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer. PSMA has a high affinity for DUPA(Ki = 8 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 60.00 | |
5 mg | In stock | $ 147.00 | |
10 mg | In stock | $ 228.00 | |
25 mg | In stock | $ 378.00 | |
50 mg | In stock | $ 538.00 | |
100 mg | In stock | $ 755.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 162.00 |
Description | DUPA(OtBu)-OH is a DUPA precursor. DUPA is used as the targeting moiety to actively deliver Docetaxel (DTX) for treatment of Prostate-Specific Membrane Antigen (PSMA) expressing prostate cancer. PSMA has a high affinity for DUPA(Ki = 8 nM). |
In vitro | DUPA is conjugated with PTX via a disulfide bond, which facilitates the rapid and differential drug release in tumor cells. The targeting ligand DUPA enhances the transport capability and selectivity of Paclitaxel (PTX) to tumor cells via prostate-specific membrane antigen (PSMA) mediated endocytosis. |
In vivo | Histological analysis indicated that DUPA-targeted Docetaxel (DTX) conjugate with longer spacer has no toxicity in major organs of treated mice. |
Molecular Weight | 488.57 |
Formula | C23H40N2O9 |
CAS No. | 1026987-94-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 125 mg/mL (255.85 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
DUPA(OtBu)-OH 1026987-94-9 Others Inhibitor DUPA(OtBu)OH DUPA(OtBu) OH inhibit inhibitor